Inspra

Eplerenone, the active ingredient in Inspra, is a selective aldosterone receptor antagonist presented as a oral tablet for oral use. It treats hypertension and heart failure, including post‑myocardial infarction, in adult patients.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Eplerenone is used to manage conditions related to excess aldosterone activity.

Hypertension: lowers blood pressure by reducing sodium retention and water overload. Heart failure: improves survival and reduces hospitalizations in patients with reduced ejection fraction. Post‑myocardial infarction heart failure: decreases risk of cardiovascular death and heart‑failure hospitalization after an acute myocardial infarction.

Adverse reactions may occur with any medication. Monitoring and prompt reporting are recommended.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Dizziness or light‑headedness. - Headache. - Nausea or abdominal discomfort. - Fatigue. - Diarrhoea.

Serious or Rare Side Effects: - Severe hyperkalaemia requiring medical intervention. - Acute renal impairment or worsening kidney function. - Angioedema or severe allergic reactions. - Hepatic dysfunction with elevated liver enzymes. - Life‑threatening hypotension. - Cardiac arrhythmias associated with electrolyte disturbances.

Patients should be evaluated for risk factors and monitored during therapy.

Monitor serum potassium: check levels before initiation and periodically thereafter. Assess renal function: evaluate creatinine and eGFR at baseline and during treatment. Avoid in severe renal impairment: contraindicated when eGFR is markedly reduced. Use caution in diabetes: increased risk of hyperkalaemia. Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Eplerenone may interact with several medicines, requiring dose adjustment or monitoring.

Major Interactions (Avoid): - ACE inhibitors or ARBs: combined use can cause significant hyperkalaemia. - Potassium‑sparing diuretics (e.g., amiloride, triamterene): additive risk of hyperkalaemia. - Potassium supplements or high‑potassium diet: may precipitate dangerous potassium elevations.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum digoxin levels may occur. - NSAIDs: can reduce renal clearance and raise potassium. - Lithium: concurrent use may increase lithium toxicity. - Thiazide diuretics: may blunt the potassium‑sparing effect. - Strong CYP3A4 inhibitors: may raise eplerenone concentrations.